Home Compare AMGN vs REGN
Stock Comparison · Single-driver result

Amgen vs Regeneron Pharmaceuticals: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Amgen carrying a narrow edge on growth. Regeneron Pharmaceuticals still has the edge on profitability, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Most of the separation is still concentrated in growth.

Trajectory Similarity
0.64
Moderately similar
Peer-set rank: #4
within Amgen Inc.'s functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.

The clearest structural overlap shows up in margin trend and revenue stability.

Similarity drivers
margin trendrevenue stability
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
AMGN
Amgen Inc.
63
Peer-Score
Signal qualityHigh
vs
REGN
Regeneron Pharmaceuticals, Inc.
61
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in growth.

Dimension spread: AMGN vs REGN Profitability 50 63 Stability 57 65 Valuation 73 80 Growth 75 22 AMGN REGN
Gap Ranking
#1 Growth +53
#2 Profitability +13
#3 Stability +8
#4 Valuation +7
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AMGN and REGN Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AMGNREGN Relative valuation Structural strength

Amgen Inc. still looks stronger overall, though current pricing looks more supportive for Regeneron Pharmaceuticals, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
On growth, Amgen Inc. ranks near the top of the group; Regeneron Pharmaceuticals, Inc. sits in the weaker half.
Profitability
Amgen Inc. sits higher in the group on profitability, adding to the overall structural advantage.
Growth — Dominant Gap
AMGN
75
REGN
22
Gap+53in favour of AMGN

Earnings growth is one contributing factor within the growth lead.

What keeps the gap from being one-sided

Regeneron Pharmaceuticals, Inc. still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.

What this means for the comparison

The main read on growth is clearer than the broader score gap.

Explore full peer positioning in AssetNext

Break down the AMGN vs REGN comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-driven comparisons

Explore how AMGN and REGN each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.